Literature DB >> 2209715

Enhancement in gastric mucus gel qualities with colloidal bismuth subcitrate administration.

J Piotrowski1, J Bilski, H Nishikawa, A Slomiany, B L Slomiany.   

Abstract

The effects of intragastric administration of an antiulcer drug, colloidal bismuth subcitrate, on the content, composition and physical properties of the mucus component of gastric mucosal barrier were investigated. The experiments were conducted with two groups of rats in which one group received twice daily for three consecutive days a dose of 100 mg/kg colloidal bismuth subcitrate, while the control group received saline. The animals were killed 16 h after the last dose, their stomachs dissected and the mucosa subjected to physicochemical measurements. The results revealed that colloidal bismuth subcitrate elicited a 49% increase in mucus gel dimension, while sulfo- and sialomucin content of the gel increased by 64 and 112%, respectively. The changes in mucus with colloidal bismuth subcitrate were accompanied by a 28% increase in H+ retardation capacity, 2.2-fold increase in viscosity, and a 26% increase in the gel hydrophobicity. The mucus elaborated in the presence of colloidal bismuth subcitrate exhibited 16% lower protein content and 68% higher content of carbohydrate than that of the control, displayed similar levels of total lipids and covalently bound fatty acids, but its phospholipid content was 32% higher. Furthermore, the mucus of the colloidal bismuth subcitrate group showed a marked increase in the proportion of the high molecular weight form of mucin. The results suggest that colloidal bismuth subcitrate is capable of the enhancement of mucus gel qualities associated with the maintenance of gastric mucosal integrity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209715     DOI: 10.1016/0014-2999(90)90666-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.